Research programme: cancer therapeutics - BionovoAlternative Names: AA102; BN-AM-206; BN-DI-110; BN-EJ-111; BN-GS-107; BN-LJ-114; BN-PC-201; BN-PL-203; BN-RU-119; BN-SA-204; BN-SG-102; BN107; BN108; VS 101
Latest Information Update: 20 Jan 2016
At a glance
- Originator Bionovo
- Mechanism of Action Apoptosis stimulants; MTORC1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer